Bioarray Therapeutics Inc.

bioarray genetics is a biotech company located in new haven ct developing and commercializing molecular tests in the oncology space. despite a broad range of breast cancer molecular tests on the market today, there is a gap in the testing regimen resulting in a trial and error approach to treatment. presently, approximately 75% of the 155,000 breast cancer patients who undergo the standard-of-care chemotherapy do not completely respond to the treatment, costing the u.s healthcare system $2.59 billion annually. the additional costs include patient morbidity and wasted time to efficacious treatment. the company's first test is a rna-based predictive test (ba100) that is able to identify breast cancer patients who will and will not realize a complete response to the traditional pre-surgery chemotherapy, resulting in over 50% reduction in wasted treatments. by properly identifying those patients that will not respond to the first-line chemotherapy treatment, bioarray’s predictive test enab